Rifampicin Alleviates Atopic Dermatitis-Like Responsein vivoandin vitro

Abstract

Atopic dermatitis (AD) is a common inflammatory skin disorder mediated by inflammatory cells, such as macrophages and mast cells. Rifampicin is mainly used for the treatment of tuberculosis. Recently, it was reported that rifampicin has anti-inflammatory and immune-suppressive activities. In this study, we investigated the effect of rifampicin on atopic dermatitis in vivo and in vitro. AD was induced by treatment with 2, 4-dinitrochlorobenzene (DNCB) in NC/Nga mice. A subset of mice was then treated with rifampicin by oral administration. The severity score and scratching behavior were alleviated in the rifampicin-treated group. Serum immunoglobulin E (IgE) and interleukin-4 (IL-4) levels were also ameliorated in mice treated with rifampicin. We next examined whether rifampicin has anti-atopic activity via suppression of mast cell activation. Rifampicin suppressed the release of β-hexosaminidase and histamine from human mast cell (HMC)-1 cultures stimulated with compound 48/80. Treatment with rifampicin also inhibited secretion of inflammatory mediators, such tumor necrosis factor-α (TNF-α) and prostaglandin D2 (PGD2), in mast cells activated by compound 48/80. The mRNA expression of cyclooxygenase 2 (COX-2) was reduced in the cells treated with rifampicin in a concentration-dependent manner. These results suggest that rifampicin can be used to treat atopic dermatitis.

Air-Spun Silk-Based Micro-/Nanofibers and Thin Films for Drug Delivery

“…The model drugs chosen for this test were reflective of many pharmaceuticals in the US pharmacopeia while providing a range of molecular weights, hydrophobicity, solubilities, and charges (Table 3). Some compounds are also in use medically already; rifampin has historically been used to treat tuberculosis [49] and has more recently been used to treat atopic dermatitis [50]. Rifampin and crystal violet also show anti-fungal and anti-bacterial activity in several studies [51,52].…”

Repositioned Drugs for Inflammatory Diseases such as Sepsis, Asthma, and Atopic Dermatitis

“…In addition, it also exhibits therapeutic effects against psoriasis in clinical practice (Bellahsene and Forsgren, 1980;Tsankov and Angelova, 2003). Rifampicin showed anti-AD activity and effectively decreased the elevated serum levels of IgE and IL-4, which are characteristic features of AD (Kim et al, 2017). Thus, rifampicin can be considered as an effective drug for the treatment of AD based on the reduction in the severity of symptoms and IgE production.…”

“…Rifampicin decreases both β-HEX and histamine secretion. Rifampicin is used as a new anti-allergic agent owing to its suppressive effect of degranulation of mast cell by controlling intracellular calcium concentrations (Kim et al, 2017). Histamine, β-HEX, PGD2, proinflammatory cytokines, TNF-α, and COX-2 Atopic dermatitis Simvastatin IL-1, IL-6, IL-8, IL-12, CD4 T-cell, Th2, ICAM-1, and VCAM-1 Sepsis and Asthma TLR2, toll-like receptor 2; TLR4, toll-like receptor 4; RAGE, receptor for advanced glycation end products; p38, protein kinase 38; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; Nrf2, nuclear factor erythroid 2 (NFE2)-related factor 2; IL, interleukin; ICAM-1, intercellular adhesion molecule 1; VCAM-1, vascular cell adhesion protein 1; mTOR, mammalian target of rapamycin; IgE, immunoglobulin E; iNOS, inducible nitric oxide synthase; ARG1, arginase 1; ARG2, arginase 2; β-HEX, β-N-acetylhexosaminidase.…”

Different macrophage polarization between drug-susceptible and multidrug-resistant pulmonary tuberculosis

“…Some antibiotics have immunomodulatory properties in vitro [12]. Rifampicin exerts anti-inflammatory effects via the suppression of nuclear factor-kappa B in neurodegenerative diseases [13,14]. Pyrazinamide treatment can influence the host immune response by reducing pro-inflammatory cytokine production in Mtb infection [15].…”